Wegovy vs Ozempic: what actually separates them in the UK

1. Start with the label, not the ladder: what each brand is licensed to do

The quickest way to sort out ozempic vs wegovy is to read the licence before you read anything about doses or results. Ozempic is authorised in the UK for adults with type 2 diabetes, to help control blood sugar. Wegovy is authorised for weight management in adults who meet the BMI criteria. Both contain semaglutide, so the confusion is understandable, but the paperwork points them at completely different patients.

This distinction is more than a technicality. The MHRA has been clear that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and prescribing outside a medicine's licence sits with the individual prescriber's judgement and responsibility. A pharmacy dispensing Ozempic "for weight loss" is stepping outside its authorised use, which is one reason a service like ours does not do it. When weight is the goal, the medicine designed and licensed for that goal is the appropriate one.

You will see the two brands described almost interchangeably online, particularly in the "ozempic or wegovy" chatter on social media. That shorthand collapses a real safety point. If you want the clean version of the pharmacology behind both names, our explainer on whether semaglutide is the same as Ozempic or Wegovy walks through why one drug wears two labels, and why the labels are not swappable.

2. Compare the doses, because that is where the real gap opens up

Once you accept they are the same active ingredient, the next honest question in the wegovy vs ozempic uk debate is dose. The two brands are titrated to different ceilings, and that ceiling shapes what the evidence can and cannot claim about weight loss.

Ozempic's diabetes dosing tops out lower than Wegovy's weight-management pathway. Wegovy for weight management starts at a low tolerability dose and steps up roughly every four weeks under a prescriber's supervision, with 2.4mg long established as the standard maintenance dose and a higher 7.2mg option now approved by the MHRA for eligible adults with obesity. The first dose exists to let your body settle rather than to treat, which is why nobody starts at the top.

That higher maintenance range is the point. Weight-loss results scale with the dose you can tolerate, and Wegovy's ladder is built to reach the doses the trials studied for weight. Ozempic's is not. So comparing their weight-loss potential dose-for-dose misses that they are aiming at different targets. Our fuller breakdown of the difference between Wegovy and Ozempic lays the schedules side by side without turning it into a how-to. Actual dosing is always set by the prescriber and detailed in the patient information leaflet, never worked out from a web page.

3. Line up the two brands on the facts that matter

Here is the practical comparison, kept to what the licences and UK guidance actually say.

The table makes the ozempic versus wegovy question look tidy, and on the essentials it is. Both are GLP-1 receptor agonists that slow how quickly the stomach empties and turn up your sense of fullness. Both are prescription-only. The divergence is licensing and dose, not mechanism.

If you like your comparisons head-to-head, our page on Ozempic versus Wegovy expands each row with the reasoning behind it. It adds up to the same conclusion: for weight, one of these is the tool for the job.

4. Check what the weight-loss evidence really shows

Because Ozempic is not a weight-loss medicine, the weight-loss trial base sits with semaglutide at the higher weight-management dose, studied under the Wegovy licence. In the STEP 1 trial, published in the New England Journal of Medicine, adults on semaglutide 2.4mg over 68 weeks saw an average body-weight reduction of around 15% alongside diet and activity changes. That is the figure the Wegovy licence rests on for standard maintenance.

The newer 7.2mg dose reported around 20.7% average weight loss over 72 weeks in its trials, narrowing the gap to the dual-agonist medicines. These are averages from clinical trials, not promises; individual results vary, and appetite reduction only works alongside changes to what you eat and how you move.

What you will not find is a bank of weight-loss trials for Ozempic, because that is not what it was developed and licensed to do. Reading across from diabetes data to weight outcomes is exactly the kind of shortcut the MHRA warns against. NICE's appraisal of semaglutide for weight management, recommended in TA875 for use within specialist services and for a maximum of two years, is the relevant reference point rather than any Ozempic study. If you are weighing effectiveness specifically, is Wegovy better than Ozempic for weight loss tackles that comparison head-on.

5. Weigh the side effects, which the two share closely

Because it is the same drug, the side-effect profile is broadly the same across both brands, led by the gut. People most commonly report feeling sick, changes to their bowels in either direction, indigestion, burping, tiredness and headaches. These tend to be most noticeable when you begin treatment or step up a dose, and for many people they ease within a couple of weeks as the body adjusts.

There is a serious but uncommon risk worth naming plainly. In January 2026 the MHRA reminded prescribers and patients that acute pancreatitis is a known side effect of GLP-1 medicines: severe stomach pain that can spread through to your back, sometimes with vomiting, needs urgent medical attention. That warning applies to semaglutide whichever brand carries it.

One practical note that catches people out on either medicine: if you use the oral contraceptive pill, the absorption question is worth raising with your prescriber, and anyone facing surgery should tell the anaesthetist they take a GLP-1. For a patient-level rundown of what to expect and when to seek help, the NHS guide to semaglutide side effects and safety is a solid, plain reference. Suspected side effects can always be reported through the MHRA's Yellow Card scheme. Our clinical team covers the aftercare side of this seven days a week, which is where questions like these usually land.

6. Understand where the NHS sits, and why the private route differs

NHS access is a common source of the ozempic or wegovy uk confusion, so it helps to separate the two. Ozempic reaches patients through type 2 diabetes care, prescribed to manage blood sugar, not weight. Wegovy for weight loss is available on the NHS only through specialist weight management services under strict criteria, and those waiting lists are commonly long.

Semaglutide's NHS weight-management use is capped at two years and delivered with multidisciplinary support, per NICE. That framework is deliberate and clinically sound, but it means a lot of people who could benefit either do not meet the threshold or face a long wait. NHS England's overview of weight management injections and the wraparound care that comes with them sets out how the specialist route works.

The private route through a regulated online pharmacy is the alternative for people who fall outside the NHS criteria or would rather not wait. That does not mean skipping the checks. With nume, every request is read the same day by a named GPhC-registered Independent Prescriber, not by software, with photo-ID and live weight verification and, in line with GPhC guidance, notification to your GP. If you are moving off a diabetes medicine and want to understand the weight-management options properly, our guidance on switching from Ozempic to Wegovy is the sensible starting point rather than doing it yourself.

7. Know what nume actually dispenses for weight loss

Here is the bottom line on what we provide, because a comparison page should not leave you guessing. nume does not dispense Ozempic for weight loss. It is not licensed for that use, and prescribing it that way is not something our pharmacy will do. If weight is what you are trying to address, the licensed injectable options through us are Wegovy and Mounjaro.

Wegovy is the weight-management form of semaglutide discussed throughout this page. Mounjaro is tirzepatide, a dual-acting medicine that reached greater average weight reduction than semaglutide 2.4mg in the head-to-head SURMOUNT-5 trial, and if you want to understand how those two options stack up against each other, our page on Wegovy vs Mounjaro sets out the differences in plain terms. Which of the two suits you depends on your health history, other medicines, tolerance and goals, not on brand recognition. That is a clinical judgement, made with you.

Everything sits under one transparent price with no subscription, no auto-renewal and every repeat clinically re-reviewed. Order before the noon cut-off on a weekday and, once approved, your treatment is dispatched the same day for free next-working-day DPD delivery in plain packaging, so you can slot it around the school run rather than a delivery window. You can start with a look at the weight-loss treatments and consultation to see what is actually on the table. Start your free consultation whenever you are ready.

Related questions we've answered

• The difference between Ozempic and Wegovy explained simply
• Can you switch between Ozempic and Wegovy?
• Wegovy vs Ozempic for weight loss
• Mounjaro vs Wegovy compared
• Wegovy: the full picture